Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CYRX Stock Forecast 2026-2027
$16.49
Current Price
$835.17M
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CYRX Price Targets
+21.3%
To High Target of $20.00
-9.0%
To Median Target of $15.00
-27.2%
To Low Target of $12.00
CYRX Price Momentum
+2.0%
1 Week Change
+13.2%
1 Month Change
+121.9%
1 Year Change
+71.8%
Year-to-Date Change
-2.0%
From 52W High of $16.83
+146.5%
From 52W Low of $6.69
📊 TOP ANALYST CALLS
Did CYRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CryoPort is one of their latest high-conviction picks.
Latest CYRX Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, CYRX has a bullish consensus with a median price target of $15.00 (ranging from $12.00 to $20.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $16.49, the median forecast implies a -9.0% downside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Hewitt at Craig-Hallum, projecting a 21.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CYRX Analyst Ratings
8
Buy
1
Hold
0
Sell
CYRX Price Target Range
Low
$12.00
Average
$15.00
High
$20.00
Current: $16.49
Latest CYRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CYRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | Matthew Hewitt | Buy | Maintains | $20.00 |
| May 20, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| May 5, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| May 5, 2026 | Needham | Buy | Maintains | $N/A | |
| May 5, 2026 | BTIG | Buy | Maintains | $N/A | |
| Mar 30, 2026 | Craig-Hallum | Buy | Initiates | $N/A | |
| Mar 4, 2026 | Needham | Buy | Maintains | $N/A | |
| Nov 5, 2025 | UBS | Buy | Maintains | $N/A | |
| Nov 5, 2025 | Needham | Buy | Maintains | $N/A | |
| Sep 18, 2025 | BTIG | Buy | Maintains | $N/A | |
| Aug 6, 2025 | Leerink Partners | Outperform | Upgrade | $N/A | |
| Aug 6, 2025 | Keybanc | Overweight | Upgrade | $N/A | |
| Jul 22, 2025 | Stephens & Co. | Helfey Hannah | Overweight | Assumes | $13.00 |
| Jul 7, 2025 | BTIG | Buy | Maintains | $N/A | |
| May 8, 2025 | Needham | Buy | Reiterates | $N/A | |
| May 5, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Apr 16, 2025 | Needham | Buy | Reiterates | $N/A | |
| Apr 16, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Apr 10, 2025 | Needham | Buy | Reiterates | $N/A | |
| Apr 1, 2025 | Roth MKM | Buy | Reiterates | $N/A |
Cryoport Inc. (CYRX) Competitors
The following stocks are similar to CryoPort based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cryoport Inc. (CYRX) Financial Data
Cryoport Inc. has a market capitalization of $835.17M with a P/E ratio of 11.8x. The company generates $182.94M in trailing twelve-month revenue with a 43.6% profit margin.
Revenue growth is +16.5% quarter-over-quarter, while maintaining an operating margin of -20.1% and return on equity of -8.2%.
Valuation Metrics
Market Cap
$835.17M
Enterprise Value
$662.95M
P/E Ratio
11.8x
PEG Ratio
-1.1x
Price/Sales
4.4x
Growth & Margins
Revenue Growth (YoY)
+16.5%
Gross Margin
+45.8%
Operating Margin
-20.1%
Net Margin
+43.6%
EPS Growth
+16.5%
Financial Health
Cash/Price Ratio
+48.6%
Current Ratio
2.1x
Debt/Equity
46.6x
ROE
-8.2%
ROA
-2.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cryoport Inc. (CYRX) Business Model
About Cryoport Inc.
What They Do
Provides temperature-controlled logistics for life sciences.
Business Model
Cryoport Inc. generates revenue by offering comprehensive temperature-controlled logistics solutions tailored for the life sciences industry. This includes services such as cryogenic transportation, monitoring, and logistics management, which are essential for the safe delivery of temperature-sensitive materials like biological samples and pharmaceuticals. The company's focus on maintaining product integrity and regulatory compliance enhances its value proposition to clients in biotechnology, pharmaceuticals, and medical research.
Additional Information
Headquartered in Nashville, Tennessee, Cryoport plays a crucial role in sustaining vital supply chains within the rapidly growing life sciences sector. Its innovative approach and commitment to quality position it as a key player in the logistics market, catering to the needs of companies relying on secure transport for their valuable materials.
Company Information
Sector
Industrials
Industry
Integrated Freight & Logistics
Employees
684
CEO
Mr. Jerrell W. Shelton
Country
United States
IPO Year
2005
Website
www.cryoportinc.comCryoport Inc. (CYRX) Latest News & Analysis
Latest News
Quick Summary
Cryoport's IntegriCell® has been chosen by Verismo Therapeutics for cryopreservation services to support their KIR-CAR programs, targeting solid tumors and B cell disorders.
Why It Matters
Cryoport's collaboration with Verismo Therapeutics enhances its service portfolio in a growing CAR T cell therapy market, potentially boosting revenue and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cryoport, Inc. (CYRX) has released its Q1 2026 earnings call transcript, detailing financial performance and updates relevant for investors.
Why It Matters
Cryoport's Q1 2026 earnings call provides insights into financial performance and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cryoport, Inc. reported Q1 2026 revenue of $47.8M, up 16% YoY. Commercial CGT revenue rose 26% to $9.1M. Full-year revenue guidance increased to $192M-$196M.
Why It Matters
Strong revenue growth across multiple segments and raised guidance indicate robust company performance, reflecting increased demand in the life sciences sector, which can positively influence stock prices.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CryoPort, Inc. (CYRX) reported a quarterly loss of $0.23 per share, exceeding the Zacks Consensus Estimate of a $0.20 loss and slightly higher than a loss of $0.22 per share from the previous year.
Why It Matters
CryoPort's larger-than-expected quarterly loss signals potential operational challenges, which may affect investor confidence and impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Cryoport, Inc. (Nasdaq: CYRX) will report Q1 2026 financial results on May 4, 2026, after U.S. markets close.
Why It Matters
Cryoport's upcoming financial results may impact stock performance and investor sentiment, reflecting the company's growth and operational efficiency in the life sciences sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Cryoport (CYRX) has a buy rating and a $9.1 price target, suggesting 17% upside by FY 2026. Q4 2025 saw double-digit revenue growth and 47.8% gross margins, with plans for positive EBITDA in H2 2026.
Why It Matters
Cryoport's buy rating and $9.1 target signal potential growth. Strong Q4 revenue and improving margins suggest financial health, while expected positive EBITDA indicates future profitability.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About CYRX Stock
What is Cryoport Inc.'s (CYRX) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Cryoport Inc. (CYRX) has a median price target of $15.00. The highest price target is $20.00 and the lowest is $12.00.
Is CYRX stock a good investment in 2027?
According to current analyst ratings, CYRX has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CYRX stock?
Wall Street analysts predict CYRX stock could reach $15.00 in the next 12 months. This represents a -9.0% decrease from the current price of $16.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cryoport Inc.'s business model?
Cryoport Inc. generates revenue by offering comprehensive temperature-controlled logistics solutions tailored for the life sciences industry. This includes services such as cryogenic transportation, monitoring, and logistics management, which are essential for the safe delivery of temperature-sensitive materials like biological samples and pharmaceuticals. The company's focus on maintaining product integrity and regulatory compliance enhances its value proposition to clients in biotechnology, pharmaceuticals, and medical research.
What is the highest forecasted price for CYRX Cryoport Inc.?
The highest price target for CYRX is $20.00 from Matthew Hewitt at Craig-Hallum, which represents a 21.3% increase from the current price of $16.49.
What is the lowest forecasted price for CYRX Cryoport Inc.?
The lowest price target for CYRX is $12.00 from at , which represents a -27.2% decrease from the current price of $16.49.
What is the overall CYRX consensus from analysts for Cryoport Inc.?
The overall analyst consensus for CYRX is bullish. Out of 5 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are CYRX stock price projections?
Stock price projections, including those for Cryoport Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:24 AM UTC